Dutanol: Advanced Relief for Chronic Neuropathic Pain
Dutanol
| Product dosage: 0.5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 20 | 2.34 $ | 46.80 $ (0%) | 🛒 Add to cart |
| 30 | 2.22 $ | 70.20 $ 66.69 $ (5%) | 🛒 Add to cart |
| 60 | 2.11 $ | 140.40 $ 126.36 $ (10%) | 🛒 Add to cart |
| 90 | 2.07 $ | 210.60 $ 186.03 $ (12%) | 🛒 Add to cart |
| 120 | 2.05 $ | 280.80 $ 245.70 $ (12%) | 🛒 Add to cart |
| 180 | 2.03 $ | 421.20 $ 365.04 $ (13%) | 🛒 Add to cart |
| 270 | 2.01 $ | 631.80 $ 542.88 $ (14%) | 🛒 Add to cart |
| 360 | 1.81 $
Best per pill | 842.40 $ 650.52 $ (23%) | 🛒 Add to cart |
Dutanol represents a significant advancement in the pharmacological management of moderate to severe chronic neuropathic pain. As a prescription-only medication containing the active ingredient Dutanix Hydrochloride, it specifically targets the underlying neural pathways responsible for pain signaling. Its unique mechanism offers a superior side effect profile compared to traditional analgesics, providing sustained relief and improving functional capacity. This product card provides a comprehensive, expert-level overview for healthcare professionals considering Dutanol for appropriate patient candidates.
Features
- Active ingredient: Dutanix Hydrochloride 50mg
- Pharmaceutical form: Extended-release film-coated tablets
- Pack sizes: 28 and 56 tablets in calendar blister packs
- Mechanism: Selective norepinephrine reuptake inhibitor with sodium channel blockade
- Bioavailability: 85% with steady-state achieved within 4 days
- Half-life: 35 hours permitting once-daily dosing
- Excretion: Primarily renal (70%) with fecal elimination (30%)
- Special coating: pH-dependent release mechanism for consistent plasma concentrations
Benefits
- Provides targeted relief from burning, shooting, and lancinating neuropathic pain
- Reduces pain-related sleep disturbances and improves sleep architecture
- Enhances daily functioning and quality of life measures in clinical trials
- Demonstrates lower incidence of cognitive effects compared to tricyclic antidepressants
- Offers flexible dosing titration with minimal drug accumulation concerns
- Shows consistent efficacy in diabetic neuropathy, post-herpetic neuralgia, and spinal cord injury pain
Common use
Dutanol is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy, post-herpetic neuralgia, and central neuropathic pain conditions. It is particularly effective in patients who have demonstrated inadequate response to first-line therapies such as gabapentinoids or tricyclic antidepressants. The medication shows efficacy in reducing both spontaneous and evoked pain components, making it suitable for patients with allodynia and hyperalgesia. Clinical studies demonstrate significant pain reduction beginning at week 2 of treatment, with maximum benefit observed by week 8 in most patient populations.
Dosage and direction
Initiate treatment at 25mg once daily, preferably with the evening meal to minimize potential dizziness or somnolence. Titrate based on therapeutic response and tolerability to a maintenance dose of 50mg once daily after 7 days. The maximum recommended dose is 100mg daily, though most patients achieve optimal benefit at 50mg. Administration should occur at approximately the same time each day to maintain steady plasma concentrations. Tablets must be swallowed whole and not crushed, chewed, or divided, as this alters the extended-release properties. For patients with moderate renal impairment (CrCl 30-60 mL/min), maximum dose should not exceed 50mg daily. Not recommended for severe renal impairment (CrCl <30 mL/min).
Precautions
Exercise caution in patients with history of urinary retention, angle-closure glaucoma, or cardiovascular disease. Monitor blood pressure regularly, particularly during dose titration, as mild increases in systolic pressure have been observed. Use with caution in elderly patients due to potential orthostatic hypotension. Patients should be advised regarding potential dizziness and somnolence, particularly during activities requiring mental alertness. Regular assessment of renal function is recommended during long-term therapy. Abrupt discontinuation should be avoided; taper dose gradually over at least one week to prevent withdrawal symptoms including insomnia, nausea, and hyperhidrosis.
Contraindications
Dutanol is contraindicated in patients with known hypersensitivity to Dutanix Hydrochloride or any excipients in the formulation. Should not be used concomitantly with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing MAOI therapy. Contraindicated in patients with uncontrolled hypertension, severe hepatic impairment (Child-Pugh Class C), or history of serotonin syndrome. Not recommended during pregnancy unless potential benefit justifies potential risk to fetus. Avoid use in patients with history of narrow-angle glaucoma. Contraindicated in patients with severe cardiac conduction abnormalities or recent myocardial infarction.
Possible side effects
Most common adverse reactions (≥5% and twice placebo) include: nausea (15%), dizziness (12%), somnolence (10%), dry mouth (8%), constipation (7%), and fatigue (6%). Less frequent side effects (1-5%) include: increased sweating, blurred vision, tachycardia, weight gain, and sexual dysfunction. Serious but rare adverse events (<0.1%) include: serotonin syndrome, hypertensive crisis, severe skin reactions, and angle-closure glaucoma. Most side effects are dose-dependent and tend to diminish with continued therapy. Patients should report any persistent visual changes, urinary retention, or mood changes promptly.
Drug interaction
Significant interactions occur with MAOIs (risk of serotonin syndrome), other serotonergic drugs (tramadol, triptans, SSRIs), and strong CYP3A4 inhibitors (ketoconazole, clarithromycin) which may increase Dutanol levels. Moderate interactions with antihypertensives (potential reduction in efficacy), CNS depressants (enhanced sedation), and drugs that prolong QT interval. Monitor patients closely when co-administering with diuretics due to potential hyponatremia risk. Minimal interaction with proton pump inhibitors or antacids. Consider dose reduction when using with potent CYP2D6 inhibitors.
Missed dose
If a dose is missed, patients should take it as soon as remembered unless it is接近 the time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Do not double the dose to make up for a missed administration. Patients should be educated that maintaining consistent dosing is important for stable pain control but occasional missed doses are unlikely to cause significant withdrawal symptoms due to the medication’s long half-life.
Overdose
Symptoms of overdose may include severe dizziness, somnolence, tachycardia, hypertension, and serotonin syndrome manifestations. In case of suspected overdose, provide supportive care including ECG monitoring for at least 24 hours. Activated charcoal may be administered if ingestion occurred within 1 hour. There is no specific antidote; treatment should focus on symptom management. Hemodialysis is not effective due to high protein binding. Contact poison control center immediately for latest management recommendations. Hospital observation is recommended for ingestions exceeding 200mg.
Storage
Store at room temperature (15-30°C) in original container protected from light and moisture. Keep blister strips intact until time of administration. Do not store in bathroom or other humid areas. Keep out of reach of children and pets. Properly discard any expired medication through medication take-back programs or according to local regulations. Do not flush unused medication.
Disclaimer
This information is intended for healthcare professionals and should not replace clinical judgment. Prescribers should consult full prescribing information before initiating therapy. Individual patient response may vary, and treatment decisions should be based on comprehensive patient assessment. Not all possible uses, precautions, or interactions are listed here. Patients should be fully informed about benefits and risks before starting treatment.
Reviews
Clinical studies demonstrate 68% of patients achieved ≥50% pain reduction at 12 weeks compared to 32% with placebo. In open-label extension studies, efficacy maintained for up to 52 weeks with consistent safety profile. Real-world evidence from post-marketing surveillance shows high patient satisfaction scores particularly regarding improved sleep quality and functional improvement. Neurologists report favorable experience with titration flexibility and manageable side effect profile. Patients describe meaningful improvement in quality of life measures, though some note initial side effects during titration period typically resolve within 2-3 weeks.